Full Chemotherapy Dose Improves Survival in Early Breast Cancer

For patients with early-stage breast cancer, surgery followed by adjuvant chemotherapy is a standard of care. However, because of the toxicities associated with chemotherapy, many patients receive reduced or modified doses. A new study sought to evaluate the impact of full versus modified-dose adjuvant chemotherapy on breast cancer survival. The investigators analyzed data from 1,302 […]

Read More

Impact of Exercise and Weight Loss on Breast Cancer Lymphedema Outcomes

Lymphedema is a common complication of curative breast cancer treatment, occurring in as many as 50% of patients undergoing axillary lymph node dissection. Because lymphedema occurs more commonly in patients with excess body weight, current guidelines recommend weight loss and home-based exercise as a strategy to manage breast cancer-related lymphedema. However, this recommendation has not […]

Read More

New Guidelines on Management of Venous Thromboembolism

Cancer patients are significantly more likely to develop venous thromboembolism (VTE) than people without cancer. Appropriate risk assessment, prophylaxis, and management of VTEs is essential to prevent the long-term complications and risk of death from deep vein thrombosis and pulmonary embolism. In a new Clinical Practice Guideline released by the American Society for Clinical Oncology […]

Read More

Antidepressants Linked to Reduced Cancer Mortality

Patients with cancer often experience depression and anxiety, and these comorbid conditions are independent risk factors for premature mortality. Many patients with cancer take antidepressants to manage these conditions, but little is known about the link between antidepressant use and mortality in patients with cancer. To evaluate this, a large, nationwide, 4-year historical cohort study […]

Read More

Nivolumab Associated With Long-Term Survival in Multiple Tumors

Immunotherapy targeting the PD-1/PD-L1 axis has become a standard component of care across multiple tumor types, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma (RCC), and others. While these agents result in durable responses, there is limited data regarding long-term survival in these patients. In a secondary analysis of the phase I CA209-003 […]

Read More

Improving Treatment of Pancreatic Cysts

The majority of patients who develop pancreatic cysts require no treatment due to the benign nature of their cysts. However, a small percentage of cysts will develop into pancreatic cancer if left untreated, and early identification and treatment of pancreatic cancer is a major factor influencing patient outcomes. Current methods at identifying which patients require […]

Read More

New Model for Predicting Cancer Outcomes

Predicting the long-term outcomes and risk of progression in patients with cancer is an important component of care that can drive treatment strategies. Unfortunately, current risk prediction models are lacking and focus primarily on pretreatment factors such as tumor phenotype and patient characteristics, which are not always indicative of long-term outcome. The need for improved […]

Read More